Abaloparatide

Overview

Abaloparatide, marketed as Tymlos, is a synthetic peptide analog of parathyroid hormone-related protein, or PTHrP. It is FDA-approved as an anabolic, or bone-building, treatment for osteoporosis. Unlike many osteoporosis drugs that work mainly by slowing bone loss, abaloparatide is designed to stimulate the formation of new bone, increasing bone mineral density and strength over a treatment course.

It is given as a once-daily injection under the skin and is generally reserved for people at high risk of fracture, such as postmenopausal women with severe osteoporosis, a history of fragility fractures, or inadequate response to other therapies. Because anabolic agents address bone density differently from antiresorptive drugs, they occupy a specific place in treatment strategy.

Abaloparatide is one of a small group of bone-forming peptides, conceptually related to teriparatide, another PTH-pathway agent. After a finite course of anabolic therapy, clinicians typically transition patients to an antiresorptive medication to preserve the gains in bone density, since the benefit can recede if no follow-on treatment is given.

How it works

Abaloparatide binds to the PTH type 1 receptor on bone cells, the same receptor activated by parathyroid hormone and PTHrP. It is engineered to favor a particular conformation of this receptor that promotes a more transient signaling response. The design goal is to tilt the balance toward bone formation while limiting the bone-resorbing effects that prolonged receptor stimulation can produce.

When the receptor is stimulated in a pulsatile, intermittent manner, as occurs with a once-daily injection, it preferentially activates osteoblasts, the cells that build new bone matrix. This contrasts with the continuous elevation of PTH-pathway signaling seen in some disease states, which tends to favor bone breakdown by osteoclasts. The intermittent dosing pattern is therefore central to the anabolic effect.

By stimulating new bone formation, abaloparatide increases bone mineral density and improves the structural quality of bone over time. Because the drug acts on calcium-regulating pathways, it can transiently raise blood and urine calcium, which is one reason laboratory monitoring and attention to calcium and vitamin D status accompany treatment.

Clinical evidence

The pivotal clinical program for abaloparatide was the ACTIVE trial, which evaluated the drug in postmenopausal women with osteoporosis. The study examined whether treatment reduced the risk of new fractures and increased bone mineral density compared with placebo, and it included a comparison arm to provide context against another anabolic agent.

An extension study followed participants after they transitioned from abaloparatide to an antiresorptive medication, addressing an important clinical question: whether the bone gained during anabolic therapy is maintained when patients move to a drug that slows bone loss. This sequential approach reflects how anabolic agents are used in practice rather than as standalone, indefinite treatments.

The evidence supports abaloparatide as an effective option for increasing bone density and reducing fracture risk in appropriately selected high-risk patients. As with any therapy, the findings apply to the populations studied, primarily postmenopausal women, and clinical decisions weigh individual fracture risk, prior treatments, and tolerability. Honest interpretation also recognizes that anabolic therapy is one phase of a longer-term plan rather than a permanent solution.

Dosing & side effects

Abaloparatide is administered as a once-daily subcutaneous injection using a pre-filled pen device, and treatment is intended for a limited duration rather than indefinite use. This guide does not provide dose amounts or injection schedules; those are set by the prescribing clinician and detailed in the product instructions. Patients are typically taught proper injection technique and rotation of injection sites.

Common side effects include dizziness, which can be related to a drop in blood pressure shortly after injection, as well as nausea, headache, palpitations, fatigue, and reactions at the injection site. Because of the risk of orthostatic symptoms, the first doses are often taken in a setting where the person can sit or lie down if needed. Elevated calcium levels can also occur, so monitoring may be advised.

Like other PTH-pathway anabolic agents, abaloparatide has carried a boxed warning regarding a potential risk of osteosarcoma observed in animal studies, and its use has historically been limited to a maximum cumulative treatment period. After completing anabolic therapy, follow-on treatment with an antiresorptive drug is generally recommended to maintain bone density gains.

Legal status

Abaloparatide is an approved prescription medication, dispensed only under the authorization of a licensed prescriber. It is not available over the counter and is not a controlled substance. Its use is guided by approved labeling that defines the patient populations and treatment duration for which it is intended.

Because abaloparatide is an injectable specialty medication, it is often handled through specialty pharmacy channels, and access may involve prior authorization or other insurance requirements. Availability of the brand, and of any biosimilar or alternative formulations, varies by country and may change over time.

Patients considering or using abaloparatide should rely on their prescriber and pharmacist for current information about appropriate candidates, treatment length, monitoring, and the transition to follow-on therapy. Regulatory frameworks emphasize that anabolic osteoporosis agents be used within their approved indications and time limits to balance benefit against the warnings carried in their labeling.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis (ACTIVE): A Randomized Clinical Trial. JAMA. 2016. Peer-reviewed study
2. Cosman F, Miller PD, Williams GC, et al. Abaloparatide followed by alendronate in postmenopausal osteoporosis (ACTIVExtend). Mayo Clin Proc. 2017. Peer-reviewed study
3. Ebina K, Etani Y, Noguchi T, et al. Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. J Bone Miner Metab. 2025. Peer-reviewed study
4. Gonnelli S, Caffarelli C. Abaloparatide. Clin Cases Miner Bone Metab. 2016. Peer-reviewed study
5. Sleeman A, Clements JN. Abaloparatide: A new pharmacological option for osteoporosis. Am J Health Syst Pharm. 2019. Peer-reviewed study
6. Thompson JC, Wanderman N, Anderson PA, et al. Abaloparatide and the Spine: A Narrative Review. Clin Interv Aging. 2020. Peer-reviewed study